Skip to main content

New York State OKs CBLPath's PCR-based Testing Services

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CBLPath today announced the New York State Department of Health has approved it to offer PCR-based testing of T-cells and B-cells.

Based in Rye Brook, NY, CBLPath provides sub-specialized anatomic pathology and molecular diagnostic laboratory services.

In a statement, David Bryant, CEO of the company, said that the industry is undergoing a convergence of anatomic, molecular, and digital pathology, combined with radiology. "With our added molecular capabilities, CBLPath is able to harness the full power of the convergence to provide better care to patients," he said.

CBLPath will expand its menu of molecular diagnostic tests during the next several months, the company said, without elaborating.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.